Sponsor: Mythic Therapeutics
Sponsor Study ID: MYTX-011-01
Study Title: A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody Drug Conjugate MYTX 011 in Subjects with Non Small Cell Lung Cancer
CTO #: 103810
NCT Number: NCT05652868
Phase: I
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Lung
Study Objectives: To evaluate the safety and tolerability of MYTX-011; To determine the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD) of MYTX-011